The shadow of generic challenges has long loomed above copyright’s iconic drug, PDE5 Inhibitor, raising questions about the outlook of similar drug holdings. While first years saw significant returns, the patent end https://pharma813373.thechapblog.com/40689501/the-copyright-and-the-pharmaceutical-industry-a-speculative-bet